People news: Optimer Therapeutics and Johnson & Johnson

Michael Chang, chairman of the board at Optimer Therapeutics and Optimer Biotechnology, was removed due to compliance/conflict of interest issues, Optimer said. The firm's VP of clinical development and CFO were also terminated, the firm said. Kurt Hartman, currently general counsel & chief compliance officer at Optimer, has been appointed acting CFO, and Hank McKinnell, former CEO of Pfizer, has replaced Chang as chairman of Optimer's board, effective immediately. In a statement, Optimer said the changes were related to "certain lapses in corporate governance practices" and to Optimer's relationship with Optimer Biotechnology, its 43%-owned independent, Taiwanese-based affiliate. The company added that it doesn't expect a material impact on revenues, operations, or on the commercialization and launch of antibiotic Dificid.

Sheri McCoy, vice chairman of the executive committee at Johnson & Johnson, resigned from the company effective April 18, J&J said. McCoy, who joined J&J in 1982 and was appointed to lead the pharmaceuticals and consumer groups in January 2011, will join Avon Products as CEO. She had lost out to incoming CEO Alex Gorsky in a race for the top job at the diversified products firm.

You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.